Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

CRMLW vs CRIS vs MP vs TGTX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CRMLW
Critical Metals Corp.

Industrial Materials

Basic MaterialsNASDAQ • US
Market Cap$437M
5Y Perf.+5354.5%
CRIS
Curis, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$76M
5Y Perf.-94.3%
MP
MP Materials Corp.

Industrial Materials

Basic MaterialsNYSE • US
Market Cap$12.28B
5Y Perf.+354.5%
TGTX
TG Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$6.87B
5Y Perf.+149.9%

CRMLW vs CRIS vs MP vs TGTX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CRMLW logoCRMLW
CRIS logoCRIS
MP logoMP
TGTX logoTGTX
IndustryIndustrial MaterialsBiotechnologyIndustrial MaterialsBiotechnology
Market Cap$437M$76M$12.28B$6.87B
Revenue (TTM)$9M$305M$700M
Net Income (TTM)$-147M$-8M$-71M$462M
Gross Margin99.5%8.3%83.0%
Operating Margin-348.4%-36.4%21.3%
Forward P/E274.3x32.3x
Total Debt$19M$2M$1.04B$261M
Cash & Equiv.$1M$5M$1.17B$79M

CRMLW vs CRIS vs MP vs TGTXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CRMLW
CRIS
MP
TGTX
StockFeb 24May 26Return
Critical Metals Cor… (CRMLW)1005454.5+5354.5%
Curis, Inc. (CRIS)1005.7-94.3%
MP Materials Corp. (MP)100454.5+354.5%
TG Therapeutics, In… (TGTX)100249.9+149.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: CRMLW vs CRIS vs MP vs TGTX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: TGTX leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Critical Metals Corp. is the stronger pick specifically for recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
CRMLW
Critical Metals Corp.
The Long-Run Compounder

CRMLW is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 42.3% 10Y total return vs MP's 5.9%
  • +23.5% vs CRIS's -72.0%
Best for: long-term compounding
CRIS
Curis, Inc.
The Specific-Use Pick

CRIS plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
MP
MP Materials Corp.
The Growth Angle

MP lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: basic materials exposure
TGTX
TG Therapeutics, Inc.
The Income Pick

TGTX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 0 yrs, beta 0.77
  • Rev growth 87.3%, EPS growth 17.5%, 3Y rev CAGR 5.0%
  • Lower volatility, beta 0.77, Low D/E 40.2%, current ratio 4.10x
  • Beta 0.77, current ratio 4.10x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthTGTX logoTGTX87.3% revenue growth vs CRIS's -13.4%
ValueTGTX logoTGTXLower P/E (32.3x vs 274.3x)
Quality / MarginsTGTX logoTGTX66.0% margin vs CRIS's -80.3%
Stability / SafetyTGTX logoTGTXBeta 0.77 vs CRMLW's 2.96
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)CRMLW logoCRMLW+23.5% vs CRIS's -72.0%
Efficiency (ROA)TGTX logoTGTX42.8% ROA vs CRMLW's -312.7%, ROIC 16.4% vs -14.6%

CRMLW vs CRIS vs MP vs TGTX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CRMLWCritical Metals Corp.

Segment breakdown not available.

CRISCuris, Inc.
FY 2025
Reportable Segment
100.0%$9M
MPMP Materials Corp.
FY 2024
Materials Segment
100.0%$204M
TGTXTG Therapeutics, Inc.
FY 2025
Product
98.5%$607M
Royalty
0.9%$6M
Other Revenue
0.6%$4M
License Revenue
0.0%$152,000

CRMLW vs CRIS vs MP vs TGTX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTGTXLAGGINGCRIS

Income & Cash Flow (Last 12 Months)

TGTX leads this category, winning 5 of 6 comparable metrics.

TGTX is the larger business by revenue, generating $700M annually — 74.2x CRIS's $9M. TGTX is the more profitable business, keeping 66.0% of every revenue dollar as net income compared to CRIS's -80.3%. On growth, TGTX holds the edge at +69.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCRMLW logoCRMLWCritical Metals C…CRIS logoCRISCuris, Inc.MP logoMPMP Materials Corp.TGTX logoTGTXTG Therapeutics, …
RevenueTrailing 12 months$9M$305M$700M
EBITDAEarnings before interest/tax-$33M-$43M$150M
Net IncomeAfter-tax profit-$8M-$71M$462M
Free Cash FlowCash after capex-$27M-$314M-$14M
Gross MarginGross profit ÷ Revenue+99.5%+8.3%+83.0%
Operating MarginEBIT ÷ Revenue-3.5%-36.4%+21.3%
Net MarginNet income ÷ Revenue-80.3%-23.3%+66.0%
FCF MarginFCF ÷ Revenue-2.9%-102.8%-2.0%
Rev. Growth (YoY)Latest quarter vs prior year-66.0%+49.1%+69.6%
EPS Growth (YoY)Latest quarter vs prior year+198.4%+121.4%+2.9%
TGTX leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

MP leads this category, winning 2 of 4 comparable metrics.
MetricCRMLW logoCRMLWCritical Metals C…CRIS logoCRISCuris, Inc.MP logoMPMP Materials Corp.TGTX logoTGTXTG Therapeutics, …
Market CapShares × price$437M$76M$12.3B$6.9B
Enterprise ValueMkt cap + debt − cash$455M$73M$12.2B$7.1B
Trailing P/EPrice ÷ TTM EPS-2.97x-0.99x-138.26x15.53x
Forward P/EPrice ÷ next-FY EPS est.274.33x32.25x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple57.07x
Price / SalesMarket cap ÷ Revenue8.04x44.59x11.15x
Price / BookPrice ÷ Book value/share13.91x4.92x10.72x
Price / FCFMarket cap ÷ FCF
MP leads this category, winning 2 of 4 comparable metrics.

Profitability & Efficiency

TGTX leads this category, winning 6 of 9 comparable metrics.

TGTX delivers a 87.4% return on equity — every $100 of shareholder capital generates $87 in annual profit, vs $-23 for CRMLW. CRIS carries lower financial leverage with a 0.30x debt-to-equity ratio, signaling a more conservative balance sheet compared to MP's 0.44x. On the Piotroski fundamental quality scale (0–9), MP scores 4/9 vs CRMLW's 1/9, reflecting mixed financial health.

MetricCRMLW logoCRMLWCritical Metals C…CRIS logoCRISCuris, Inc.MP logoMPMP Materials Corp.TGTX logoTGTXTG Therapeutics, …
ROE (TTM)Return on equity-23.3%-138.8%-3.7%+87.4%
ROA (TTM)Return on assets-3.1%-26.1%-2.0%+42.8%
ROICReturn on invested capital-14.6%-4.7%+16.4%
ROCEReturn on capital employed-21.7%-2.3%-4.2%+17.7%
Piotroski ScoreFundamental quality 0–91344
Debt / EquityFinancial leverage0.30x0.44x0.40x
Net DebtTotal debt minus cash$18M-$3M-$123M$182M
Cash & Equiv.Liquid assets$1M$5M$1.2B$79M
Total DebtShort + long-term debt$19M$2M$1.0B$261M
Interest CoverageEBIT ÷ Interest expense-0.08x-107.35x-2.80x5.67x
TGTX leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CRMLW leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in CRMLW five years ago would be worth $432,693 today (with dividends reinvested), compared to $28 for CRIS. Over the past 12 months, CRMLW leads with a +2353.4% total return vs CRIS's -72.0%. The 3-year compound annual growth rate (CAGR) favors CRMLW at 2.5% vs CRIS's -67.0% — a key indicator of consistent wealth creation.

MetricCRMLW logoCRMLWCritical Metals C…CRIS logoCRISCuris, Inc.MP logoMPMP Materials Corp.TGTX logoTGTXTG Therapeutics, …
YTD ReturnYear-to-date+97.8%-41.1%+25.8%+46.9%
1-Year ReturnPast 12 months+2353.4%-72.0%+192.7%+23.5%
3-Year ReturnCumulative with dividends+4226.9%-96.4%+221.7%+30.0%
5-Year ReturnCumulative with dividends+4226.9%-99.7%+149.7%+7.0%
10-Year ReturnCumulative with dividends+4226.9%-99.7%+591.3%+436.5%
CAGR (3Y)Annualised 3-year return+2.5%-67.0%+47.6%+9.1%
CRMLW leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

TGTX leads this category, winning 2 of 2 comparable metrics.

TGTX is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than CRMLW's 2.96 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TGTX currently trades 97.8% from its 52-week high vs CRIS's 18.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCRMLW logoCRMLWCritical Metals C…CRIS logoCRISCuris, Inc.MP logoMPMP Materials Corp.TGTX logoTGTXTG Therapeutics, …
Beta (5Y)Sensitivity to S&P 5002.96x1.87x1.40x0.77x
52-Week HighHighest price in past year$20.73$3.13$100.25$44.00
52-Week LowLowest price in past year$0.17$0.49$18.64$25.28
% of 52W HighCurrent price vs 52-week peak+26.0%+18.4%+69.0%+97.8%
RSI (14)Momentum oscillator 0–10056.648.966.874.2
Avg Volume (50D)Average daily shares traded47K444K5.6M2.1M
TGTX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: MP as "Buy", TGTX as "Buy". Consensus price targets imply 13.2% upside for MP (target: $78) vs -9.4% for TGTX (target: $39).

MetricCRMLW logoCRMLWCritical Metals C…CRIS logoCRISCuris, Inc.MP logoMPMP Materials Corp.TGTX logoTGTXTG Therapeutics, …
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$78.25$39.00
# AnalystsCovering analysts1113
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+1.3%
Insufficient data to determine a leader in this category.
Key Takeaway

TGTX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MP leads in 1 (Valuation Metrics).

Best OverallTG Therapeutics, Inc. (TGTX)Leads 3 of 6 categories
Loading custom metrics...

CRMLW vs CRIS vs MP vs TGTX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is CRMLW or CRIS or MP or TGTX a better buy right now?

For growth investors, TG Therapeutics, Inc.

(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus -13. 4% for Curis, Inc. (CRIS). TG Therapeutics, Inc. (TGTX) offers the better valuation at 15. 5x trailing P/E (32. 3x forward), making it the more compelling value choice. Analysts rate MP Materials Corp. (MP) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CRMLW or CRIS or MP or TGTX?

On forward P/E, TG Therapeutics, Inc.

is actually cheaper at 32. 3x.

03

Which is the better long-term investment — CRMLW or CRIS or MP or TGTX?

Over the past 5 years, Critical Metals Corp.

(CRMLW) delivered a total return of +42. 3%, compared to -99. 7% for Curis, Inc. (CRIS). Over 10 years, the gap is even starker: CRMLW returned +42. 3% versus CRIS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CRMLW or CRIS or MP or TGTX?

By beta (market sensitivity over 5 years), TG Therapeutics, Inc.

(TGTX) is the lower-risk stock at 0. 77β versus Critical Metals Corp. 's 2. 96β — meaning CRMLW is approximately 283% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Curis, Inc. (CRIS) carries a lower debt/equity ratio of 30% versus 44% for MP Materials Corp. — giving it more financial flexibility in a downturn.

05

Which is growing faster — CRMLW or CRIS or MP or TGTX?

By revenue growth (latest reported year), TG Therapeutics, Inc.

(TGTX) is pulling ahead at 87. 3% versus -13. 4% for Curis, Inc. (CRIS). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to -154. 6% for Critical Metals Corp.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CRMLW or CRIS or MP or TGTX?

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus -80. 3% for Curis, Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 20. 0% versus -348. 4% for CRIS. At the gross margin level — before operating expenses — CRIS leads at 99. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CRMLW or CRIS or MP or TGTX more undervalued right now?

On forward earnings alone, TG Therapeutics, Inc.

(TGTX) trades at 32. 3x forward P/E versus 274. 3x for MP Materials Corp. — 242. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MP: 13. 2% to $78. 25.

08

Which pays a better dividend — CRMLW or CRIS or MP or TGTX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is CRMLW or CRIS or MP or TGTX better for a retirement portfolio?

For long-horizon retirement investors, TG Therapeutics, Inc.

(TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77), +436. 5% 10Y return). Critical Metals Corp. (CRMLW) carries a higher beta of 2. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TGTX: +436. 5%, CRMLW: +42. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CRMLW and CRIS and MP and TGTX?

These companies operate in different sectors (CRMLW (Basic Materials) and CRIS (Healthcare) and MP (Basic Materials) and TGTX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CRMLW is a small-cap quality compounder stock; CRIS is a small-cap quality compounder stock; MP is a mid-cap high-growth stock; TGTX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

CRMLW

Quality Business

  • Sector: Basic Materials
  • Market Cap > $100B
Run This Screen
Stocks Like

CRIS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 59%
Run This Screen
Stocks Like

MP

High-Growth Disruptor

  • Sector: Basic Materials
  • Market Cap > $100B
  • Revenue Growth > 24%
Run This Screen
Stocks Like

TGTX

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 34%
  • Net Margin > 39%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.